Immunotherapy has revolutionized oncology remarkably and gained great improvements in
cancer therapy. However, tumor immunotherapy still encounters serious challenges …

Recent advances in the synthesis of nanomaterials with diagnostic and therapeutic
capabilities have been rapidly reshaping the landscape of precision medicine. Impressive …

Personalized cancer vaccines (PCVs) are reinvigorating vaccine strategies in cancer
immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV …

Therapeutic cancer vaccines, which are designed to amplify tumor-specific T cell responses,
have been envisioned as one of the most powerful tools for effective cancer immunotherapy …

Adoptive immunotherapies based on the transfer of functional immune cells hold great
promise in treating a wide range of malignant diseases, especially cancers, autoimmune …

Polymers, lipids, scaffolds, microneedles, and other biomaterials are rapidly emerging as
technologies to improve the efficacy of vaccines against infectious disease and …

Nanovaccine‐based immunotherapy (NBI) has received greater attention recently for its
potential to prime tumor‐specific immunity and establish a long‐term immune memory that …

In recent decades, peptides, which can possess high potency, excellent selectivity, and low
toxicity, have emerged as promising therapeutics for cancer applications. Combined with an …

Immunotherapy continues to be in the spotlight of oncology therapy research in the past few
years and has been proven to be a promising option to modulate one's innate and adaptive …

Checkpoint blockade immunotherapy has shown great potential in clinical cancer therapy,
but the body's systemic immune must be fully activated and generates a positive tumor …